查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2022-2029 年全球神經保護市場
市場調查報告書
商品編碼
1169020

2022-2029 年全球神經保護市場

Global Neuroprotection Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

在預測期內 (2022-2029)，全球神經保護市場規模預計將以 8.2% 的複合年增長率增長。

神經保護是一類導致神經系統、結構、細胞和功能恢復、拯救和再生的作用。 有多種神經化學調節劑會損害神經系統。 它是通過抑制任何導致細胞功能障礙的致病級聯反應來預防神經元細胞死亡的治療能力。

市場動態

推動全球神經保護市場的主要因素是世界範圍內神經退行性疾□□病患病率的增加、研發支出的增加以及公眾對這些神經保護產品的認識。 越來越多的新產品推出將有助於神經保護市場的增長。

增加研發投資、增加新產品發布和增加藥物發現預計將推動市場增長。

這些神經保護產品在預防和治療各種神經退行性疾□□病（例如帕金森氏病和多發性硬化症）中的採用以及新產品的不斷推出正在推動神經保護市場。我來了。 不斷上升的神經系統疾病也在推動市場增長。 許多醫療保健公司正在加緊研發活動以開發新產品。

神經保護用於多種疾病，包括中風、外傷、阿爾茨海默病、帕金森病、多發性硬化症、亨廷頓舞蹈病和中風脊髓性肌萎縮症。 對於這些應用，由於案例數量的增加，市場正在全球範圍內擴大。 此外，預計主要參與者提供的技術先進的產品也將在市場增長中發揮重要作用。

各種新產品的發布、監管批准和研究正在為市場的增長做出貢獻。 例如，2022 年 7 月 5 日，Biogen Inc. 和 Eisai Co., Ltd. of Tokyo and Cambridge 宣布，lecanemab 的生物製品許可申請 (BLA) 獲得批准，lecanemab 是一種在研抗澱粉樣蛋白 (AB) 纖維狀抗體由美國食品和藥物管理局宣布已被該局接受。 該抗體用於治療輕度認知障礙伴阿爾茨海默病和腦澱粉樣病變。

與神經保護相關的副作用和高成本預計會阻礙市場增長。

但是，由於某些產品和藥物會相互作用並釋放不需要的副作用，因此未成年人會面臨一些副作用。 一些研究表明，補充維生素 E 會使某些人的癡呆症和大腦功能惡化。

據報導，使用抗興奮劑後會出現各種副作用，包括視力模糊、腿部腫脹、意識模糊和幻覺。 神經保護劑治療的高成本也是神經保護市場增長的限制因素。

COVID-19 影響分析

疫情對全球金融預期、運營和危機應對策略產生了負面影響。 COVID-19 的爆發嚴重影響了醫療保健行業。 由於 COVID 病例數量的增加，各種研究和臨床試驗被推遲或推遲，神經保護市場經歷了與 COVID 相關的巨大損失。 世界各地正在發生各種舉措、產品發布、創新、合作和合併，推動了市場的增長。 例如，2020 年 4 月 21 日，諾華公司在醫學雜誌《美國神經病學協會神經病學四月特刊》上發表了 Maisent Data。 該數據提供了臨床證據，證明 Maizent 可以減緩繼發性進行性多發性硬化症患者的殘疾進展並改善認知功能。

內容

第1章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第4章市場動態

  • 市場影響因素
    • 司機
      • 增加研發投資
      • 新產品發布和藥物發現
      • 神經系統疾病的發病率增加
    • 約束因素
      • 飆升的治療費用
      • 與藥物治療相關的副作用
    • 商機
    • 影響分析

第5章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 定價分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按產品類型

  • 抗炎藥
  • 自由基清除劑
  • 抗興奮劑
  • 細胞凋亡抑製劑
  • 鐵螯合劑
  • 神經營養因子
  • 興奮劑
  • 基因治療

第 8 章按類型

  • 預防
  • 治療

第 9 章按應用

  • 阿爾茨海默氏癡呆症
  • 帕金森病
  • 多發性硬化症
  • 中風
  • 脊髓性肌萎縮症
  • 亨廷頓舞蹈症
  • 克雅氏病 (CJD)
  • 其他

第 10 章最終用戶

  • 醫院
  • 專科診所
  • 其他

第11章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第12章競爭格局

  • 主要發展和戰略
  • 公司股票分析
  • 產品基準
  • 值得關注的主要公司名單

第13章公司簡介

  • F. Hoffmann-La Roche AG
    • 公司概況
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • Eli Lilly and Company
  • Novartis AG
  • AstraZeneca
  • Teva Pharmaceutical Industries Ltd.
  • Biogen
  • Astrocyte Pharmaceuticals, Inc.
  • AbbVie Inc.
  • Medtronic
  • Merck KGaA

第14章 全球神經保護市場-DataM

簡介目錄
Product Code: DMMD1229

Market Overview

The global neuroprotection market size was valued at US$ XX million in 2022 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 8.2% during the forecast period (2022-2029).

Neuroprotection is a kind of effect that can result in recovery, salvage and regeneration of the nervous system, structure, cells and function. There are various neurochemical modulators that damage the nervous system. It is the capability for therapy for neuronal cell death prevention by inhibiting any pathogenic cascade that results in cell dysfunction.

Market Dynamics

The major factors driving the global neuroprotection market are an increase in the number of neurodegenerative disorders globally, rising research and development expenditure and awareness among the population regarding these neuroprotection products. An increase in novel product launches contributes to the growth of the neuroprotection market.

The increasing investment in R&D, rising novel product launches, and drug discovery are expected to drive the market's growth.

The rising adoption of these neuroprotection products for the prevention or treatment of various neurodegenerative disorders, such as Parkinson's disease and multiple sclerosis, and the rising number of novel product launches drive the neuroprotection market. An increase in neurological diseases is also aiding the market growth. There has been an increase in R&D activities by many healthcare companies to develop novel products.

Neuroprotection is used in various disorders such as stroke, trauma, Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, and stroke spinal muscular atrophy. The market for these applications is increasing worldwide due to the increasing number of cases. Moreover, the availability of technologically advanced products by key players is also expected to play a vital role in the market's growth.

Various novel product launches, regulatory approvals and research studies contribute to the market's growth. For instance, in July 5, 2022, Biogen Inc and TOKYO and CAMBRIDGE Eisai Co Ltd announced their Biologics License Application (BLA) for lecanemab, an anti-amyloid beta (AB) protofibril investigational antibody got accepted by the U.S. Food and Drug Administration. This antibody is used for mild cognitive impairment treatment that is caused due to Alzheimer's disease and mild AD with amyloid pathology present in the brain.

The side effects associated with neuroprotection and the high cost are expected to hamper the market's growth.

However, the minor population faces several side effects, as several products and medicines interact and release unwanted side effects. Several research studies suggest that dementia and brain function in some people can worsen due to vitamin E supplementation.

Various side effects are reported after using anti-excitotoxic agents, such as blurred vision, swelling of feet, confusion and hallucinations. The high cost of the treatment with neuroprotection is another factor limiting the neuroprotection market's growth.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The neuroprotection market has experienced huge losses due to COVID, as various research and clinical trials got delayed and postponed due to the increasing cases of COVID. Various initiatives, product launches, innovations, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in April 21, 2020, Novartis announced its Mayzent data in the medical journal, supplemental issue of neurology of the American Academy of Neurology of April. This data provides clinical evidence that Mayzent slows down the progression of physical disability and offers cognitive benefits in people having secondary progressive multiple sclerosis.

Segment Analysis

The free-radical trapping agent segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The free-radical trapping agent segment is the highest market holder in the global neuroprotection market. The global neuroprotection market is segmented based on product type: anti-inflammatory agents, free radical trapping agents, anti-excitotoxic agents, apoptosis inhibitors, iron chelators, neurotrophic factors, stimulants and gene therapy. The free-radical trapping agent segment is the largest market shareholder due to its better efficacy and results, increasing neurogenerative disorders and rising adoption of these neuroprotection products.

The free-radical trapping agents convert the disease-causing and damaging free radical cells into molecules that are more stable than earlier and easier to manage by the body. Antioxidants generally interact with these free radicals and reduce their impact. These can be found in plant-based food supplements. It has been observed that Vitamin E also possesses antioxidant properties in Alzheimer's.

The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drive the market's growth. For instance, in June 24, 2021, Eli Lilly and Company announced that its Alzheimer's disease antibody therapy, donanemab, had received breakthrough therapy designation by the United States Food and Drug Administration. This designation accelerates the development and review of drugs utilized for severe condition treatment if evidence of preliminary clinical trials suggests that it may show improvement over the marketed therapies with FDA approval.

Geographical Analysis

North America holds the largest market share in the global neuroprotection market.

North America dominates the global neuroprotection market, primarily due to its large population, excellent medical infrastructure, and the rising number of neurodegenerative disorders. According to Alzheimer's Association report, in 2022, around 6.5 million Americans aged 65 will have Alzheimer's. Around 1 out of 9 people 65 years or older have dementia; by 2050, this is expected to reach around 12.7 million. The increasing brain health issues, such as depression and dementia, boost the demand for neuroprotection products. Depression, stress, and anxiety are common mental illnesses among adolescents and millennials in the region.

Increasing expenditure on healthcare and raising awareness among people are also contributing to the market's growth in this region. Advancement of applications of neuroprotection in Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Huntington's Disease, Creutzfeldt-Jakob disease (CJD), Stroke, Spinal Muscular Atrophy and Others, increase in pharmaceutical establishment across the region and government approvals and the presence of key players in the region are contributing to the growth of the neuroprotection market.

Moreover, the growing number of product launches is responsible for the market's growth. Many key developments, regulatory approvals, technological advancements, collaborations, and agreements are taking place in this region. For instance, in July 26, 2022, Biogen Inc. announced its acceptance of a New Drug Application for an investigational drug, tofersen, utilized for superoxide dismutase 1 (SOD1) (ALS) amyotrophic lateral sclerosis. Priority review has been granted to the application, and further prescription drug user-free act action date have also been given.

Competitive Landscape

The neuroprotection market is moderately competitive with local and global companies' presence. F. Hoffmann-La Roche AG, Eli Lilly and Company, Novartis AG, AstraZeneca, Teva Pharmaceutical Industries Ltd., Biogen, Astrocyte Pharmaceuticals, Inc., AbbVie Inc., Medtronic, Merck KGaA and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in Oct 26, 2021, Teva Pharmaceuticals Industries Ltd. Announced its strategic collaboration with MODAG GmbH on worldwide exclusive licensing and development of anle 138b, a lead compound of MODAG and sery433, a related compound. Anle 138b is a small molecule candidate targeting disease modification for several neurological disorders, including multiple system atrophy.

F. Hoffmann-La Roche AG.

Overview: Roche is a healthcare company that provides in-vitro diagnostics and supplies solutions that are innovative as well as transformative in various crucial disease areas. It works in two divisions: Pharmaceuticals and diagnostics. It was established in 1896 and is headquartered in Basel, Switzerland.

Product Portfolio:

Ocrelizumab: Ocrevus is a monoclonal humanized antibody that targets CD20-positive B cells with a major role in multiple sclerosis. This therapy is the first approved for primary progressive multiple sclerosis and relapsing forms of multiple sclerosis. It is in the final stage and will be available in the market in 2023.

Key Developments: In February 15, 2022, Roche announced its agreement with Aquinnah Pharmaceuticals for amyotrophic lateral sclerosis and neurodegenerative diseases by advancing brain penetrant oral small molecules development.

The global neuroprotection market report would provide access to approx.: 45+ market data tables, 40+ figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in investment in research and development
      • 4.1.1.2. Novel product launches and drug discovery
      • 4.1.1.3. Increasing incidence of neurological disorders
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of treatment
      • 4.1.2.2. Side effects associated with medications
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Anti-Inflammatory Agents *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Free Radical Trapping Agents
  • 7.4. Anti-Excitotoxic Agents
  • 7.5. Apoptosis Inhibitors
  • 7.6. Iron Chelators
  • 7.7. Neurotrophic Factors
  • 7.8. Stimulants
  • 7.9. Gene Therapy

8. By Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.1.2. Market Attractiveness Index, By Type
  • 8.2. Prevention *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Treatment

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Alzheimer's Disease *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Parkinson's Disease
  • 9.4. Multiple Sclerosis
  • 9.5. Stroke
  • 9.6. Spinal Muscular Atrophy
  • 9.7. Huntington's Disease
  • 9.8. Creutzfeldt-Jakob disease (CJD)
  • 9.9. Others

10. By End-User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.1.2. Market Attractiveness Index, By End-User
  • 10.2. Hospitals *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Specialty Clinics
  • 10.4. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type Product Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.6.1. U.S.
      • 11.2.6.2. Canada
      • 11.2.6.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.6.1. Germany
      • 11.3.6.2. U.K.
      • 11.3.6.3. France
      • 11.3.6.4. Italy
      • 11.3.6.5. Spain
      • 11.3.6.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.6.1. Brazil
      • 11.4.6.2. Argentina
      • 11.4.6.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.6.1. China
      • 11.5.6.2. India
      • 11.5.6.3. Japan
      • 11.5.6.4. Australia
      • 11.5.6.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Products Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. F. Hoffmann-La Roche AG*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Eli Lilly and Company
  • 13.3. Novartis AG
  • 13.4. AstraZeneca
  • 13.5. Teva Pharmaceutical Industries Ltd.
  • 13.6. Biogen
  • 13.7. Astrocyte Pharmaceuticals, Inc.
  • 13.8. AbbVie Inc.
  • 13.9. Medtronic
  • 13.10. Merck KGaA

LIST NOT EXHAUSTIVE

14. Global Neuroprotection Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and End-User
  • 14.3. Contact Us